In Vitro Evaluation of the Cytotoxic Effects of Rupatadine on Various Cancer Cell Lines
Abstract
Inflammation is a cancer-related process that contributes to the development and progression of malignancies. Targeting molecules involved in the inflammatory process may be a promising strategy for cancer prevention and treatment. In this context, antihistamines are emerging as a key component of this strategy. Rupatadine (Rup), which specifically targets histamine-1 and platelet-activating factor receptors, is considered a potential therapeutic candidate in this context. This study was conducted to determine the effect of the antihistamine Rup on various cancer cell lines. In the study, human ovarian (A2780), colon (Caco-2) and prostate cancer (LNCaP) cell lines were used. After incubating the cells for 24 hours with Rup concentrations of 1, 5, 25, 50, and 100 µM, cytotoxicity levels were assessed using the MTT assay method. Cell viability results and Rup's inhibitory concentration 50 (IC₅₀) values were calculated using the GraphPad Prism 8 program. Group comparisons were performed using the Kruskal-Wallis H test, and when statistically significant differences were found between groups, multiple comparisons were performed using the Bonferroni-corrected Mann Whitney U test (p< .05). Rup concentrations significantly reduced cell viability in the A2780, Caco-2 and LNCaP cell lines (p< .05). These results indicate that Rup, which exhibits antihistamine activity, may possess anticancer potential and could be considered a therapeutic candidate for various cancer types due to its ability to significantly reduce cell viability in different cancer cell lines.
Keywords
Antihistamine, Colon cancer, Cytotoxicity, Ovarian cancer, Prostate cancer, Rupatadine
Supporting Institution
This study is not supported by any institution.
Ethical Statement
This study does not involve any human participants or animal experiments. Therefore, ethical approval was not required in accordance with the guidelines of the International Committee of Medical Journal Editors (ICMJE). The research was conducted using commercially available cell lines, and no primary human or animal tissues were used.
References
- [1] NCI. (2023). What Is Cancer? reached 20 June 2024. https://www.cancer.gov/about-cancer/understanding/what-is-cancer.
- [2] GLOBOCON. (2023). All Cancers. reached 20 June 2024. https://gco.iarc.who.int/today/en/fact-sheetscancers.
- [3] Taniguchi K, Karin M. NF-κB, inflammation, immunity and cancer: coming of age. Nature reviews Immunology, 2018; 18(5): 309-324.
- [4] Colotta F, Allavena P, Sica A, Garlanda C, et al. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis, 2009; 30(7): 1073-1081.
- [5] Thompson PA, Khatami M, Baglole CJ, Sun J, et al. Environmental immune disruptors, inflammation and cancer risk. Carcinogenesis, 2015; 36(Suppl_1): S232-S253.
- [6] Melnikova V, Bar-Eli M. Inflammation and melanoma growth and metastasis: the role of platelet-activating factor (PAF) and its receptor. Cancer and Metastasis Reviews, 2007; 26: 359-371.
- [7] Jancar S, Chammas R. PAF receptor and tumor growth. Current Drug Targets, 2014; 15(10): 982-987.
- [8] Kay J, Thadhani E, Samson L, Engelward B. Inflammation-induced DNA damage, mutations and cancer. DNA Repair, 2019; 83: 102673.
- [9] Cao X, Wang X, Wang H, Xu G, et al. Systemic inflammation status relates to anti–inflammatory drug benefit and survival in rectal cancer. Journal of Surgical Research, 2022; 269: 249-259.
- [10] Khandia R, Munjal A. Interplay between inflammation and cancer. Advances in Protein Chemistry and Structural Biology, 2020; 119: 199-245.